Department of Cancer Studies and Molecular Medicine, George Porter Building, University of Leicester, Leicester LE1 7RH, UK.
Eur J Med Chem. 2012 Aug;54:952-8. doi: 10.1016/j.ejmech.2012.06.031. Epub 2012 Jun 22.
A library of flavonol analogues was synthesised and evaluated as potential anticancer agents against a human prostate cancer cell line, 22rν1. Compounds 3, 8 and 11 (IC(50) 2.6, 3.3 and 4.0 μM respectively) showed potent cancer cell growth inhibition, comparable to the lead compound 3',4',5'-trimethoxyflavonol (1) (IC(50) 3.1 μM) and superior to the naturally occurring flavonols quercetin (16) and fisetin (22) (both >15 μM). Results indicate that the 3',4',5'- arrangement of either hydroxy (OH) or methoxy (OMe) residues is important for growth arrest of these cells and that the OMe analogues may be superior to their OH counterparts. Compounds 1, 3, 8 and 11 warrant further investigation as potential agents for the management of prostate cancer.
合成了黄酮醇类似物库,并对其进行了评估,以作为针对人前列腺癌细胞系 22rν1 的潜在抗癌剂。化合物 3、8 和 11(IC50 分别为 2.6、3.3 和 4.0 μM)表现出强烈的癌细胞生长抑制作用,与先导化合物 3',4',5'-三甲氧基黄酮醇(1)(IC50 为 3.1 μM)相当,优于天然存在的类黄酮槲皮素(16)和非瑟酮(22)(均 >15 μM)。结果表明,3',4',5'-位上的羟基(OH)或甲氧基(OMe)残基的排列对于这些细胞的生长抑制很重要,并且 OMe 类似物可能优于其 OH 对应物。化合物 1、3、8 和 11 有必要作为治疗前列腺癌的潜在药物进一步研究。